TD-HW412016

Leronlimab(TD-HW412016) is a research-grade recombinant antibody targetingCD195. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG4-kappa

Monoclonal

C-C CKR-5, CC-CKR-5, CMKBR5, HIV-1 fusion coreceptor, CHEMR13, CCR5, C-C chemokine receptor type 5, CD195, CCR-5

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P51681

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

HuPRO-140, PA-14, PRO-140, 674782-26-4

Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.• Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19., PMID:34530915• CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells., PMID:25840792• Retinopathy severity correlates with RANTES concentrations and CCR 5-positive microvesicles in diabetes., PMID:31891363• Effects of conventional CPB and mini-CPB on neutrophils CD162, CD166 and CD195 expression., PMID:27625334• Acute response of peripheral CCr5 chemoreceptor and NK cells in individuals submitted to a single session of low-intensity strength exercise with blood flow restriction., PMID:25643617• Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy., PMID:27781132

SDS-PAGE for Research Grade Leronlimab.

For research use only. Not suitable for clinical or therapeutic use.